JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB176843

Anti-Histone H3 (citrulline R2) antibody [EPR17703]

5

(1 리뷰)

|

(17 제품이 사용된 논문 )

Rabbit Recombinant Monoclonal H3 citrulline R2 antibody. Suitable for IP, I-ELISA, WB, PepArr and reacts with Transfected cell lysate, Mouse, Human, Recombinant fragment - Human samples. Cited in 17 publications.
6 이미지
Immunoprecipitation - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
  • IP

Supplier Data

Immunoprecipitation - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)

Histone H3 was immunoprecipitated from 0.35 mg HEK-293T (human embryonic kidney) transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours, whole cell lysate 10 ug with ab176843 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab176843 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution. Lane 1 : HEK-293T (human embryonic kidney) transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours, whole cell lysate 10 ug

Lane 2 : ab176843 IP in HEK-293T transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab176843 in HEK-293T transfected with PADI4 expression vector containing a GFP-tag treated with 10 mM calcium chloride and 10 µM lonomycin for 4 hours whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 min

All lanes:

Immunoprecipitation - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (ab176843)

Predicted band size: 15 kDa

false

Indirect ELISA - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
  • I-ELISA

Supplier Data

Indirect ELISA - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)

ELISA analysis of Human Histone H3 (ci recombinant protein at 100 ng/ml with ab176843. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
  • WB

Supplier Data

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)

Blocking/Dilution buffer : 5% NFDM/TBST.

PADI4 catalyzes the citrullination of arginine residues of histone proteins.

All lanes:

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (ab176843) at 1/500 dilution

Lane 1:

MCF7 (Human breast adenocarcinoma cell line) cells transfected with vector control

Lane 2:

MCF7 (Human breast adenocarcinoma cell line) cells transfected with PADI4

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 15 kDa

Observed band size: 15 kDa

false

Exposure time: 30s

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
  • WB

Supplier Data

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)

Blocking/Dilution buffer : 5% NFDM/TBST.

PADI4 catalyzes the citrullination of arginine residues of histone proteins.

All lanes:

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (ab176843) at 1/500 dilution

Lane 1:

NIH/3T3 (Mouse embyro fibroblast cells) cells transfected with vector control

Lane 2:

NIH/3T3 (Mouse embyro fibroblast cells) cells transfected with PADI4

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

Predicted band size: 15 kDa

Observed band size: 15 kDa

false

Exposure time: 30s

Peptide Array - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
  • PepArr

Unknown

Peptide Array - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)

ab176843 was tested in Peptide Array against 501 different modified and unmodified histone peptides; each peptide is printed on the array at six concentrations (each in triplicate).
Circle area represents affinity between the antibody and a peptide : all antigen-containing peptides are displayed as red circles, all other peptides as blue circles. The affinity is calculated as area under curve when antibody binding values are plotted against the corresponding peptide concentration. Each circle area is normalized to the peptide with the strongest affinity.
The complete dataset, including full list of all peptides and information on the position of each peptide in the diagram, is available under the Product Protocol section.

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)
  • WB

CiteAb

Western blot - Anti-Histone H3 (citrulline R2) antibody [EPR17703] (AB176843)

Histone H3 (citrulline R2) western blot using anti-Histone H3 (citrulline R2) antibody [EPR17703] ab176843. Publication image and figure legend from Zhou, Y., Chen, B., et al., 2017, Front Immunol, PubMed 28993780.

ab176843 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab176843 please see the product overview.

Citrullination of extracellular substrates by intact neutrophils or neutrophil-conditioned media. (A) Upper panel, anti-citrullinated fibrinogen immunoblot of the supernatant from the incubation of fibrinogen for the indicated times in the presence of human neutrophils (lanes 1–7). Lane 7, fibrinogen was omitted. Lane 8 only contained fibrinogen. Lane 9, fibrinogen and recombinant PAD4. Lane 10, neutrophil-conditioned media. Lane 11, neutrophil with 2 mM EGTA. Lower panel, Coomassie Brilliant blue staining as a loading control. The bands corresponding to the α, β, and γ chains of fibrinogen are indicated. Note that α-fibrinogen is rapidly degraded by neutrophil-associated proteases. (B) Control immunoblot with anti-GAPDH, an intracellular protein, to demonstrate that significant lysis of neutrophils occurs only after 4 h of incubation with Triton X at 37°C under the experimental conditions. (C) Upper panel, anti-citrullinated histone H3 immunoblot of the supernatant from the incubation of histone H3 for the indicated time periods in the presence of human neutrophils (lanes 1–7). Lane 7, histone was omitted. Lane 8 only contained histone H3. Lane 9 contained histone H3 and recombinant PAD4. Lane 10, neutrophil-conditioned media. Lane 11, neutrophil with 2 mM EGTA. Note that citrullinated histone H3 is also cleaved by neutrophil-associated protease(s) to generate a slightly smaller protein. Lower panel, anti-histone H3 immunoblot as a loading control. This antibody does not recognize the proteolytically cleaved H3. (D) A similar experiment performed in the presence of an MMP inhibitor, a protease inhibitor cocktail, or both, as indicated. Lower panel, Coomassie Brilliant blue staining as a loading control. All data are representative of five independent experiments with different donors.

false

관련 conjugated 항체와 다양한 조성의 항체 (1)

  • Carrier free

    Anti-Histone H3 (citrulline R2) antibody [EPR17703] - BSA and Azide free

주요 정보

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR17703

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Human

Applications

PepArr, I-ELISA, WB, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

<p>Treatment is required for detection of the target protein. See Protocol section for detailed information. 更多详细信息请参阅 Protocol 部分.</p>

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "PepArr" : {"fullname" : "Peptide Array", "shortname":"PepArr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "IELISA-species-checked": "guaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p></p>", "PepArr-species-checked": "testedAndGuaranteed", "PepArr-species-dilution-info": "", "PepArr-species-notes": "<p></p>" }, "Mouse": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "IELISA-species-checked": "guaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p></p>", "PepArr-species-checked": "guaranteed", "PepArr-species-dilution-info": "", "PepArr-species-notes": "" }, "Recombinant fragment - Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "0.1 µg/mL", "IELISA-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "PepArr-species-checked": "notRecommended", "PepArr-species-dilution-info": "", "PepArr-species-notes": "" }, "Transfected cell lysate": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "PepArr-species-checked": "notRecommended", "PepArr-species-dilution-info": "", "PepArr-species-notes": "" } } }

제품 세부 정보

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

특성 및 보관 정보

제형
Liquid
Purification 테크닉
Affinity purification Protein A
보관 버퍼
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
배송 시 보관 조건
Conditional Ambient
적절한 단기 보관 기간
1-2 weeks
적절한 단기 보관 조건
+4°C
적절한 장기 보관 조건
-20°C
분주 정보
Upon delivery aliquot
보관 정보
Avoid freeze / thaw cycle

제품 프로토콜

For this product, it's our understanding that no specific protocols are required. You can visit:
Treatment Conditions:

Chemical treatment is required for detection of endogenous citrullinated proteins in cell lines. PADs (including PADI2 and PADI4) are the enzymes that hydrolyze arginine to citrulline, in the presence of Ca2+ and ionomycin. Please refer to PMID: 26360112

Controls:
- Mock (no transfection)
- Transfection reagent–only control
- Empty vector control
- Vehicle control for chemical treatment

Generation of PADI2 or PADI4 overexpression cell line and treatment with CaCl2/Ionomycin:

1. Prior to transfection with PADI2 or PADI4 expression vector, seed cells in complete medium and place in a 37°C, 5% CO2 incubator for 24 hours or until cells reach 70-80% confluence.

For a single T-175 flask we recommend seeding the following common cell lines as follows in 30 mL media:
- HEK-293T: 1x107 cells
- MCF7: 2.5-4x106 cells
- NIH3T3: 4-5x106 cells

2. Once cells have reached confluence, prepare the PADI2 or PADI4 expression vector for transfection using your preferred method (PMID: 33976969).
3. 24-48 hours after transfection, remove the medium from the cells and replace with fresh complete medium containing 10 mM CaCl2 (ab285384) and 10 uM Ionomycin (ab120116) and incubate for 2-4 hours.

Key Considerations:
For alternative cell lines, you should confirm the transfectability, growth rate, and sensitivity of the cell line to the planned chemical treatment. Incubation times and treatment length may need to be adjusted.

Western Blot Conditions:
Recommended SDS-PAGE Gel Type: 4-20% Tris-glycine
Recommended Running Buffer: Tris-Glycine-SDS
Primary: 1/500 dilution at 4°C overnight or room temperature for 1 hour
Blocking: 5% NFDM at room temperature for 1 hour

Positive Control: Cell line overexpressing PADI4 and treated with CaCl2/Ionomycin
Negative Control: Cell line overexpressing PADI4

Additional resources:
Lysate preparation protocol
Lysate preparation protocol - nuclear proteins
Lysate preparation protocol - low molecular weight proteins
Western blot troubleshooting

타겟 정보

Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
See full target information H3C1 citrulline R2

대체 명칭 보기

H3FA, HIST1H3A, H3C2, H3FL, HIST1H3B, H3C3, H3FC HIST1H3C, H3C4, H3FB, HIST1H3D, H3C6, H3FD, HIST1H3E, H3C7, H3FI, HIST1H3F, H3C8, H3FH, HIST1H3G, H3C10, H3FK, HIST1H3H, H3C11, H3FF, HIST1H3I, H3C12, H3FJ, HIST1H3J, H3C1, H3FC, HIST1H3C, Histone H3.1, Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, Histone H3/h, Histone H3/i, Histone H3/j, Histone H3/k, Histone H3/l, H3R2cit

제품이 사용된 논문 (17)

Recent publications for all applications. Explore the 전체 목록and refine your search

Nature communications 16:5393 PubMed40562767

2025

PADI4-mediated citrullination of histone H3 stimulates HIV-1 transcription.

Applications

Unspecified application

Species

Unspecified reactive species

Luca Love,Bianca B Jütte,Birgitta Lindqvist,Hannah Rohdjess,Oscar Kieri,Piotr Nowak,J Peter Svensson

Nature communications 15:9746 PubMed39528459

2024

A cyclic peptide toolkit reveals mechanistic principles of peptidylarginine deiminase IV regulation.

Applications

Unspecified application

Species

Unspecified reactive species

M Teresa Bertran,Robert Walmsley,Thomas Cummings,Iker Valle Aramburu,Donald J Benton,Rocio Mora Molina,Jayalini Assalaarachchi,Maria Chasampalioti,Tessa Swanton,Dhira Joshi,Stefania Federico,Hanneke Okkenhaug,Lu Yu,David Oxley,Simon Walker,Venizelos Papayannopoulos,Hiroaki Suga,Maria A Christophorou,Louise J Walport

Nature structural & molecular biology 31:977-995 PubMed38321148

2024

A quantitative and site-specific atlas of the citrullinome reveals widespread existence of citrullination and insights into PADI4 substrates.

Applications

Unspecified application

Species

Unspecified reactive species

Alexandra S Rebak,Ivo A Hendriks,Jonas D Elsborg,Sara C Buch-Larsen,Claus H Nielsen,Lene Terslev,Rebecca Kirsch,Dres Damgaard,Nadezhda T Doncheva,Caroline Lennartsson,Martin Rykær,Lars J Jensen,Maria A Christophorou,Michael L Nielsen

Philosophical transactions of the Royal Society of London. Series B, Biological sciences 378:20220248 PubMed37778388

2023

Small molecule activates citrullination through targeting PAD2.

Applications

Unspecified application

Species

Unspecified reactive species

Xue Zhang,Mengzhen Shen,Huimin Zhu,Junjie Zhang,Min Yang,Kaiyan Su,Yirong Zhang,Wei Fu,Xisong Ke,Yi Qu

Molecular biology and evolution 39: PubMed34730808

2021

Citrullination Was Introduced into Animals by Horizontal Gene Transfer from Cyanobacteria.

Applications

Unspecified application

Species

Unspecified reactive species

Thomas F M Cummings,Kevin Gori,Luis Sanchez-Pulido,Gavriil Gavriilidis,David Moi,Abigail R Wilson,Elizabeth Murchison,Christophe Dessimoz,Chris P Ponting,Maria A Christophorou

Frontiers in immunology 12:716250 PubMed34737738

2021

Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4.

Applications

Unspecified application

Species

Unspecified reactive species

María Teresa Martín Monreal,Alexandra Stripp Rebak,Laura Massarenti,Santanu Mondal,Ladislav Šenolt,Niels Ødum,Michael L Nielsen,Paul R Thompson,Claus H Nielsen,Dres Damgaard

Frontiers in immunology 12:675315 PubMed34616390

2021

Early and Late Processes Driving NET Formation, and the Autocrine/Paracrine Role of Endogenous RAGE Ligands.

Applications

Unspecified application

Species

Unspecified reactive species

Olga Tatsiy,Vanessa de Carvalho Oliveira,Hugo Tshivuadi Mosha,Patrick P McDonald

Nature immunology 22:1107-1117 PubMed34385713

2021

Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity.

Applications

Unspecified application

Species

Unspecified reactive species

Pengchong Li,Mengdi Jiang,Ketian Li,Hao Li,Yangzhong Zhou,Xinyue Xiao,Yue Xu,Suzanne Krishfield,Peter E Lipsky,George C Tsokos,Xuan Zhang

Cell 184:3915-3935.e21 PubMed34174187

2021

The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.

Applications

Unspecified application

Species

Unspecified reactive species

Florian Wimmers,Michele Donato,Alex Kuo,Tal Ashuach,Shakti Gupta,Chunfeng Li,Mai Dvorak,Mariko Hinton Foecke,Sarah E Chang,Thomas Hagan,Sanne E De Jong,Holden T Maecker,Robbert van der Most,Peggie Cheung,Mario Cortese,Steven E Bosinger,Mark Davis,Nadine Rouphael,Shankar Subramaniam,Nir Yosef,Paul J Utz,Purvesh Khatri,Bali Pulendran

Journal of thrombosis and haemostasis : JTH 18:2732-2743 PubMed32654410

2020

Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma.

Applications

Unspecified application

Species

Unspecified reactive species

Charlotte Thålin,Katherina Aguilera,Nathan W Hall,Matthew R Marunde,Jonathan M Burg,Axel Rosell,Maud Daleskog,Maja Månsson,Yohei Hisada,Matthew J Meiners,Zu-Wen Sun,Matthew F Whelihan,Marcus A Cheek,Sarah A Howard,Shruti Saxena-Beem,Denis F Noubouossie,Nigel S Key,Saira Z Sheikh,Michael-Christopher Keogh,Martis W Cowles,Staffan Lundström,Nigel Mackman,Håkan Wallén,Andrea L Johnstone
제품이 사용된 논문 모두 보기
peptideArrayWebsite
en

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com